A Nature Medicine paper published in January 2024 describes eight cases of iatrogenic Alzheimer's disease in individuals who received cadaveric pituitary‐derived human growth hormone. This evidence concerns the gene GH1 and early-onset autosomal dominant Alzheimer disease.